Former President Joe Biden’s diagnosis of what his office called an “aggressive” form of prostate cancer on Sunday, May 18, is calling attention to a disease that is diagnosed in hundreds of thousands ...

Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding ...

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

A new study reveals that some men who are diagnosed with “Grade Group one” (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

Grade group 1 prostate cancer assessment should include PSA, stage, and disease volume for accurate risk evaluation. Active surveillance is safe for most low-risk patients, but higher-risk features ...

News that former President Joseph Biden has advanced prostate cancer has revived long-standing questions about the benefits versus the harms of a blood test that screens for the most commonly ...

Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...